Plasmodium vivax is the most geographically widespread cause of human malaria and is
responsible for the majority of cases outside of the African continent. While great progress …

Malaria caused by Plasmodium vivax is comparatively less virulent than Plasmodium
falciparum, which can also lead to severe disease and death. It shows a wide geographical …

Polymorphisms in the Plasmodium falciparum multidrug resistance protein 1 (pfmdr1) gene
and the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene alter the …

Artemisinin-based combination therapies (ACTs) have been vital in reducing malaria
mortality rates since the 2000s. Their efficacy, however, is threatened by the emergence and …

Malaria is the fifth most lethal parasitic infections in the world. Herein, five new series of
aminoalcohol quinolines including fifty-two compounds were designed, synthesized and …

Antimalarial compounds with dual therapeutic and transmission-blocking activity are desired
as high-value partners for combination therapies. Here, we report the identification and …

Mutations in a Plasmodium de-ubiquitinase UBP1 have been linked to antimalarial drug
resistance. However, the UBP1-mediated drug-resistant mechanism remains unknown …

The parasite Plasmodium falciparum is the most lethal species of Plasmodium to cause
serious malaria infection in humans, and with resistance developing rapidly novel treatment …

Background The analysis of single nucleotide polymorphism (SNPs) in drug-resistance
associated genes is a commonly used strategy for the surveillance of anti-malarial drug …

Having faced increased clinical treatment failures with dihydroartemisinin-piperaquine (DHA-
PPQ), Cambodia swapped the first line artemisinin-based combination therapy (ACT) from …